<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, higher doses than previously tested and prolonged duration of treatment for responding patients were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>Over the dose range of 1.5-8 mg/kg/week, lintuzumab was well tolerated, and a maximum tolerated dose was not defined </plain></SENT>
<SENT sid="3" pm="."><plain>The most common adverse event was transient chills with the initial lintuzumab infusion (39%) </plain></SENT>
<SENT sid="4" pm="."><plain>Responses were observed in 7 of 17 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>: morphologic complete remission (n = 4), partial remission (n = 2), and morphologic <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free state (n = 1) </plain></SENT>
<SENT sid="5" pm="."><plain>Of 14 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath>, 1 patient had major hematologic improvement and 9 patients had stable disease </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity </plain></SENT>
</text></document>